RxDoctor Payments DataLook up a doctor →

Howard Fine, MD

Retina Specialist · New Brunswick, NJNPI 1295810059

Payments from drug & device makers

$1,697,037in general payments, 2019–2025

Across 659 payments — averaging $2575.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$544K
  • Bayer$364K
  • Genentech, Inc.$341K
  • Regeneron Healthcare Solutions, Inc.$259K
  • Apellis Pharmaceuticals, Inc.$86K
  • Genentech USA, Inc.$34K
  • plus $69K from 15 others
$347in research payments, 2019–2025

Across 4 payments — averaging $86.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$347

What the payments were for

  • Consulting fees$40,3184%
  • Speaking & faculty fees$877,69692%
  • Travel & lodging$28,9293%
  • Food & beverage$7,5621%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,697,037 in reported general payments places this provider in the 95th percentile of 35 retina specialist providers in New Jersey.

See all retina specialist providers in New Jersey

Medicare billing

Part B allowed, 2024
$5,620,732
Medicare patients
1,421
Services billed
37,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate106$5,745
Bromfenac Sodium18$4,263
Ketorolac Tromethamine31$980
Latanoprost57$550
Atropine Sulfate13$494
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat25$365
Timolol Maleate41$281
Brimonidine Tartrate34$238
Dorzolamide Hcl13$209
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim14$102

Paid to pharmacies, not to this prescriber.

Other retina specialist in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →